Lower Switch Rate in Depressed Patients With Bipolar II Than Bipolar I Disorder Treated Adjunctively With Second-Generation Antidepressants
Abstract
OBJECTIVES: The authors compared the switch rate into hypomania/mania in depressed patients treated with second-generation antidepressants who had either bipolar I or bipolar II disorder. METHOD: In a 10-week trial, 184 outpatients with bipolar depression (134 with bipolar I disorder, 48 with bipolar II disorder, two with bipolar disorder not otherwise specified) were treated with one of three antidepressants as an adjunct to mood stabilizers. The patients’ switch rates were assessed. Switch was defined as a Young Mania Rating Scale (YMRS) score >13 or a Clinical Global Impression (CGI) mania score ≥3 (mildly ill). RESULTS: Depressed subjects with bipolar II disorder had a significantly lower acute switch rate into hypomania/mania when either YMRS or CGI criteria were used to define switch. CONCLUSIONS: These data suggest that depressed patients with bipolar II disorder are less vulnerable than those with bipolar I disorder to switch into hypomania/mania when treated with an antidepressant adjunctive to a mood stabilizer.
Most patients with bipolar I or bipolar II disorder spend more time in the depressed than the manic phase of their illness (1). Antidepressant medications play a pivotal role as adjunctive treatment to mood stabilizers for depressive episodes. Concerns exist, however, about the potential of antidepressants to cause patients to switch into hypomania or mania (2, 3). Data in some (4, 5) but not all (6) studies suggest that patients with bipolar II disorder may be less vulnerable to switching poles when treated with antidepressants. We sought to explore whether a differential risk for switching exists, hypothesizing that there would be no significant differences in switch rates between depressed patients with bipolar I versus II disorder treated adjunctively with antidepressants.
Method
Patients who were participants in the Stanley Foundation Bipolar Network (7–9) provided written informed consent for participation in a 10-week randomized clinical trial for bipolar depression as approved by each local institutional review board. Inclusion criteria included having a DSM-IV depressive episode despite ongoing treatment with mood stabilizers within minimum specified blood level guidelines (lithium >0.7 meq/liter; valproate ≥50 μg/ml; carbamazepine ≥4 μg/ml). To exclude any patient with mixed mania, patients were included only if they had a score ≥16 on the Inventory of Depressive Symptomatology (10) and a mania subscale score of 1 (not ill) on the Clinical Global Impression (CGI) bipolar illness scale (11).
One hundred eighty-four bipolar depressed patients (134 [73%] with bipolar I disorder; 48 [26%] with bipolar II disorder; two [1%] with bipolar disorder not otherwise specified) were randomly assigned to receive one of three mechanistically different antidepressants—bupropion (N=55), sertraline (N=62), or venlafaxine (N=67)—as adjunctive treatment to one or more mood stabilizers. Patients were followed for 10 weeks. Doses of mood stabilizers, antipsychotics, and any ongoing benzodiazepines were held steady. Each antidepressant had an identically matched placebo, and all patients took two sets of study drug compounds throughout (one active and one placebo). Starting and maximal doses were 75 and 450 mg/day for bupropion; 50 and 200 mg/day for sertraline; and 37.5 and 375 mg/day for venlafaxine.
Patients were seen weekly for 2 weeks, then biweekly for 8 weeks. Assessments based on the Inventory of Depressive Symptomatology, the mania subscale of the CGI bipolar disorder scale, and the Young Mania Rating Scale (YMRS) (12) were obtained at each visit. The reliability and sensitivity of the latter two scales for detecting different severities of hypomania/mania have been documented (11, 12). A switch into hypomania/mania was operationalized as a score ≥3 (mildly ill) on the CGI mania subscale, or, more conservatively, a score >13 on the YMRS.
Results
Table 1 displays demographic, course of illness, and medication variables for the 182 depressed patients with bipolar I or bipolar II disorder. There were no significant demographic differences between groups. Antidepressant medications were distributed equally in patients with bipolar I and bipolar II disorder (χ2=0.53, df=2, p=0.77). Significantly more patients with bipolar I disorder than those with bipolar II disorder were taking valproate or atypical antipsychotics.
Switch rates into hypomania or mania based on YMRS criteria over the 10-week trial were low. Patients with bipolar II disorder were significantly less likely than those with bipolar I disorder to switch: 16 (12%) of the 134 patients with bipolar I disorder met YMRS criteria for a switch into mania, compared with one (2%) of the 48 patients with bipolar II disorder (χ2=4.4, df=1, p<0.04). Eleven patients with bipolar I disorder (8%) switched into hypomania (YMRS score=14–19), and five (4%) switched into mania (YMRS score=20–25). The one patient with bipolar II disorder who made a switch switched into hypomania (YMRS score=13.5). Two patients with bipolar I disorder (2%) and no patients with bipolar II disorder were hospitalized for mania. Using the less conservative CGI criteria, we found that 29 subjects with bipolar I disorder (22%) and four subjects with bipolar II disorder (8%) switched into hypomania/mania (χ2=4.22, df=1, p<0.05).
Our data add to a small literature (4, 5, 13, 14) suggesting lower acute switch rates as a function of bipolar subtype. Our study suggests that depressed patients with bipolar II disorder may be less vulnerable than those with bipolar I disorder to switch poles even into mild hypomania when given an antidepressant adjunctively with a mood stabilizer. Two other treatment studies (15, 16) suggested that antidepressant monotherapy may result in very low switch rates into hypomania or mania in depressed subjects with bipolar II disorder. Although antidepressant monotherapy is not supported in bipolar depression treatment guidelines, these studies nonetheless suggest a low vulnerability to switching in the bipolar II disorder population.
Several limitations exist in the current study. First, significantly more patients with bipolar I disorder than patients with bipolar II disorder received valproate and antipsychotics. However, this should have conferred greater protection against switch for the patients with bipolar I disorder, biasing results toward the null. Second, it is possible that standard rating scales for mania are less sensitive for measuring hypomania, and thus the switch of subjects with bipolar II disorder would be less likely to be observed. We used low cutoffs on the scales, however, to capture very minor changes in mood.
Since depression is a major cause of disability, finding the optimal treatment approach is critical, but the task of identifying patients vulnerable to switching and effectively treating such patients without causing harm (e.g., causing a switch into hypomania or mania or cycling) remains a challenge. Our study reports switch rates from an acute 10-week trial. A recent study employing NIMH Life Chart Methodology (17) also demonstrated lower switch rates in patients with bipolar II disorder than patients with bipolar I disorder during longer-term follow-up. If low switch rates in patients with bipolar II disorder with acute and continuation antidepressant exposure are confirmed, different treatment algorithms for bipolar II disorder versus bipolar I disorder may be recommended.
 |
Received Jan. 19, 2005; revision received June 16, 2005; accepted July 12, 2005. From the Department of Psychiatry and Biobehavioral Sciences and Department of Biostatistics, School of Public Health, University of California, Los Angeles; Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center; Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; Department of Psychiatry, University Medical Center Groningen, the Netherlands; Biological Psychiatry Branch, NIMH, NIH, Bethesda, Md.; Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Mental Health Care Line and General Clinical Research Center, and Cincinnati VA Medical Center, Cincinnati; Altrech Institute for Mental Health Care, Utrecht, the Netherlands; and Department of Psychiatry, Ludwig-Maxmilians-Universitat Munich. Address correspondence and reprint requests to Dr. Altshuler, 300 UCLA Medical Plaza, Suite 1544, Box 957057, Los Angeles, CA 90095-7057; [email protected] (e-mail).Supported by the Stanley Medical Research Institute and NIMH. Drug and matching placebo were supplied by GlaxoSmithKline, Pfizer U.S. Pharmaceuticals, and Wyeth Pharmaceuticals.The authors thank Sun Hwang for additional statistical support, Jeffrey Hatef and Sean O’Neill for technical support and randomization tables, and Teri English for administrative assistance.
1. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, Endicott J, Keller M: Long-term symptomatic status of bipolar I vs bipolar II disorders. Int J Neuropsychopharmacol 2003; 6:127–137Crossref, Medline, Google Scholar
2. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM: Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161:1537–1547Link, Google Scholar
3. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Kupka RW, Denicoff K, Nolen WA, Grunze H, Martinez MI, Post RM: Antidepressant augmentation in bipolar depression: a higher ratio of full switches to subthreshold hypomanias on venlafaxine than sertraline or bupropion in acute and continuation trials. Am J Psychiatry 2006; 163:232–239Link, Google Scholar
4. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT: Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002; 105:427–430Crossref, Medline, Google Scholar
5. Serretti A, Artioli P, Zanardi R, Rossini D: Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:751–757Crossref, Medline, Google Scholar
6. Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M: Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001; 62:249–255Crossref, Medline, Google Scholar
7. Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE Jr, McElroy SL, Denicoff KD, Leverich GS, Kupka R, Nolen WA: Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3:259–265Crossref, Medline, Google Scholar
8. Post RM, Nolen WA, Kupka RW, Denicoff KD, Leverich GS, Keck PE Jr, McElroy SL, Rush AJ, Suppes T, Altshuler LL, Frye MA, Grunze H, Walden J: The Stanley Foundation Bipolar Network, I: rationale and methods. Br J Psychiatry Suppl 2001; 41:S169-S176Google Scholar
9. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R, Frye MA, Bickel M, Post RM: The Stanley Foundation Bipolar Treatment Outcome Network, II: demographics and illness characteristics of the first 261 patients. J Affect Disord 2001; 67:45–59Crossref, Medline, Google Scholar
10. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C: The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986; 18:65–87Crossref, Medline, Google Scholar
11. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159–171Crossref, Medline, Google Scholar
12. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429–435Crossref, Medline, Google Scholar
13. Peet M: Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164:549–550Crossref, Medline, Google Scholar
14. Kupfer DJ, Chengappa KN, Gelenberg AJ, Hirschfeld RM, Goldberg JF, Sachs GS, Grochocinski VJ, Houck PR, Kolar AB: Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry 2001; 62:985–990Crossref, Medline, Google Scholar
15. Amsterdam JD, Shults J, Brunswick DJ, Hundert M: Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression—low manic switch rate. Bipolar Disord 2004; 6:75–81Crossref, Medline, Google Scholar
16. Simpson SG, DePaulo JR: Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol 1991; 11:52–54Crossref, Medline, Google Scholar
17. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka R, Nolen WA, Grunze H, Martinez M, Post RM: The Range of Hypo/Manic Severities on Antidepressants: A Randomized, Double Blind Comparison of Bupropion, Sertraline, and Venlafaxine Using Daily NIMH-LCM Ratings. Acta Psychiatr Scand Suppl 2004; 39Google Scholar
